NCT07094893View on ClinicalTrials.gov

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

280

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2030

Conditions

Colorectal Cancer

Interventions

DRUG

Cetuximab (EGFR inhibitor)

Administration according to the labels of each IMP.

DRUG

Bevacizumab

Administration according to the labels of each IMP.

DRUG

Irinotecan (CPT-11)

Administration according to the labels of each IMP.

DRUG

Oxaliplatin

Administration according to the labels of each IMP.

DRUG

Leucovorin and 5-FU

Administration according to the labels of each IMP.

DRUG

Capecitabine

Administration according to the labels of each IMP.

All Listed Sponsors

collaborator

Merck Serono International SA

INDUSTRY

lead

Gruppo Oncologico del Nord-Ovest

OTHER